Follow-up to evaluate the the immunogenicity % safety of GSK Biologicals’ MMRV vaccine given as a two-dose schedule in the second year of life, as compared to separate administration of GSK Biologicals’ Priorix® % Varilrix®.
Combined Measles, Mumps, Rubella, Varicella Vaccine
Measles; Mumps; Rubella; Varicella
Phase 3
This is a Year 1 follow up study to 208136/038. An annotated case report form is not available for this study. A blank case report form will be provided.
February 2015